{"schema_version":"1","generated_at":"2026-11-21T13:28:04.395Z","data_as_of":null,"url":"https://www.findmykol.com/kol/warren-dinges","json_url":"https://www.findmykol.com/kol/warren-dinges/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"warren-dinges","name":"Warren Dinges","credential":"MD, PhD","specialty":"Infectious Disease","specialty_raw":"Infectious Disease","therapeutic_area":"Infectious Disease","therapeutic_areas":["Infectious Disease"],"city":"Seattle","state":"WA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Warren Dinges is an Infectious Disease physician. OpenAlex indexes 16 publications with 414 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Infectious Disease"]},"scholarship":{"works_count":16,"cited_by_count":414,"h_index":8,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":14,"shown":3,"withheld":11,"rows":[{"payer":"Gilead Sciences, Inc.","program_year":2025,"amount_usd":33308.77,"payment_count":61},{"payer":"Gilead Sciences, Inc.","program_year":2024,"amount_usd":38545.35,"payment_count":79},{"payer":"Gilead Sciences, Inc.","program_year":2023,"amount_usd":32656.74,"payment_count":73}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":11,"areas_shown":3,"areas":[{"area":"Cardiovascular","share_pct":39.6,"classes_total":10,"classes":[{"class":"Statin","setting":"prescribed","share_pct":13.4,"drugs":[{"name":"Rosuvastatin Calcium","share_pct":49.3},{"name":"Atorvastatin Calcium","share_pct":42.3},{"name":"Pravastatin Sodium","share_pct":8.5}],"max_beneficiaries":null},{"class":"ACE inhibitor","setting":"prescribed","share_pct":7.4,"drugs":[{"name":"Lisinopril","share_pct":100}],"max_beneficiaries":32}]},{"area":"Nervous system","share_pct":18.3,"classes_total":9,"classes":[{"class":"Benzodiazepine","setting":"prescribed","share_pct":3.9,"drugs":[{"name":"Clonazepam","share_pct":41.7},{"name":"Alprazolam","share_pct":25},{"name":"Diazepam","share_pct":19},{"name":"Temazepam","share_pct":14.3}],"max_beneficiaries":null},{"class":"SNRI","setting":"prescribed","share_pct":3.1,"drugs":[{"name":"Duloxetine Hcl","share_pct":43.3},{"name":"Desvenlafaxine Succinate Er","share_pct":32.8},{"name":"Venlafaxine Hcl Er","share_pct":23.9}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":15.2,"classes_total":10,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":3.5,"drugs":[{"name":"Valacyclovir","share_pct":100}],"max_beneficiaries":16},{"class":"Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor","setting":"prescribed","share_pct":3.2,"drugs":[{"name":"Juluca","share_pct":36.2},{"name":"Dovato","share_pct":29},{"name":"Tivicay","share_pct":18.8},{"name":"Isentress","share_pct":15.9}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":16,"shown":5,"withheld":11,"matched_by":"OpenAlex author record","recent":[{"title":"Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis","year":2026,"journal":"Journal of Comparative Effectiveness Research","source_url":"https://doi.org/10.57264/cer-2026-0013","status":"verified"},{"title":"SA21 Comparative Safety of B/F/TAF vs. Other Antiretroviral Therapy Regimens for Treatment-Experienced People With HIV-1: A Systematic Literature Review and Indirect Comparisons Using Multilevel Network Meta-Regression","year":2025,"journal":"Value in Health","source_url":"https://doi.org/10.1016/j.jval.2025.09.2963","status":"verified"},{"title":"Long-term follow-up of HIV-1-infected adults who received the F4/AS01 B HIV-1 vaccine candidate in two randomised controlled trials","year":2018,"journal":"Vaccine","source_url":"https://doi.org/10.1016/j.vaccine.2018.03.043","status":"verified"},{"title":"The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults","year":2016,"journal":"Medicine","source_url":"https://doi.org/10.1097/md.0000000000002673","status":"verified"},{"title":"Why isn’t cefadroxil used more often?","year":2016,"journal":"American Journal of Health-System Pharmacy","source_url":"https://doi.org/10.2146/ajhp150841","status":"verified"}],"source":"works"},"similar":[{"name":"Thomas Walsh","slug":"thomas-walsh","institution":"Cornell University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/thomas-walsh","json_url":"https://www.findmykol.com/kol/thomas-walsh/profile.json"},{"name":"Douglas Richman","slug":"douglas-richman","institution":"University of California San Diego","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/douglas-richman","json_url":"https://www.findmykol.com/kol/douglas-richman/profile.json"},{"name":"Henry Masur","slug":"henry-masur","institution":"National Institutes of Health","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/henry-masur","json_url":"https://www.findmykol.com/kol/henry-masur/profile.json"},{"name":"Vance Fowler","slug":"vance-fowler","institution":"Duke University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/vance-fowler","json_url":"https://www.findmykol.com/kol/vance-fowler/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":11,"publications":11}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}